TCGA, SEER, and BraTS Dominate Neuro-Oncology Big Data Research, External Validation Rare

Among 3,608 neuro-oncology studies, 65% used TCGA, 14% SEER, 13% BraTS; <1% assessed functional outcomes, 90% relied on single dataset, external validation rare.

• Functional or quality-of-life outcomes were examined in fewer than 1% of studies.
• External validation and longitudinal modeling were rare, with 90% of studies relying on a single dataset.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.